Researchers track Long-Term survival in stomach cancer patients after new drug
NCT ID NCT07547787
First seen Apr 25, 2026 · Last updated May 13, 2026 · Updated 2 times
Summary
This study follows up with people who have advanced stomach cancer and previously took part in trials of the drug cadonilimab. The goal is to collect long-term data on how long patients live. No new treatment is given—this is an observational study to see if the drug offers lasting survival benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.